By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Current study results on Oncology have been published. According to news reporting originating from Ann Arbor, Michigan, by NewsRx correspondents, research stated, "Survivin is expressed in tumor cells, including acute myeloid leukemia (AML), regulates mitosis, and prevents tumor cell death. The antisense oligonucleotide sodium LY2181308 (LY2181308) inhibits survivin expression and may cause cell cycle arrest and restore apoptosis in AML."
Our news editors obtained a quote from the research from the University of Michigan Comprehensive Cancer Center, "In this study, the safety, pharmacokinetics, and pharmacodynamics/efficacy of LY2181308 was examined in AML patients, first in a cohort with monotherapy (n=8) and then post-amendment in a cohort with the combination of cytarabine and idarubicin treatment (n=16). LY2181308 was administered with a loading dosage of three consecutive daily infusions of 750 mg followed by weekly intravenous (IV) maintenance doses of 750 mg. Cytarabine 1.5 g/m2 was administered as a 4-hour IV infusion on Days 3, 4, and 5 of Cycle 1, and idarubicin 12 mg/m2 was administered as a 30-minute IV infusion on Days 3, 4, and 5 of Cycle 1. Cytarabine and idarubicin were administered on Days 1, 2, and 3 of each subsequent 28-day?cycle. Reduction of survivin was evaluated in peripheral blasts and bone marrow. Single-agent LY2181308 was well tolerated and survivin was reduced only in patients with a high survivin expression. In combination with chemotherapy, 4/16 patients had complete responses, 1/16 patients had incomplete responses, and 4/16 patients had cytoreduction. Nine patients died on study: 6 (monotherapy), 3 (combination). LY2181308 alone is well tolerated in patients with AML."
According to the news editors, the research concluded: "In combination with cytarabine and idarubicin, LY2181308 does not appear to cause additional toxicity, and has shown some clinical benefit needing confirmation in future clinical trials."
For more information on this research see: Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Investigational New Drugs, 2013;31(4):1023-34. Investigational New Drugs can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. (Springer - www.springer.com; Investigational New Drugs - www.springerlink.com/content/0167-6997/)
The news editors report that additional information may be obtained by contacting H.P. Erba, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, United States. Additional authors for this research include H. Sayar, M. Juckett, M. Lahn, V. Andre, S. Callies, S. Schmidt, S. Kadam, J.T. Brandt, D. Van Bockstaele and M. Andreeff (see also Oncology).
Publisher contact information for the journal Investigational New Drugs is: Springer, 233 Spring Street, New York, NY 10013, USA.
Keywords for this news article include: Antimetabolites, Antineoplastics, Antisense Technology, Biotechnology, Pharmaceuticals, Drugs, Michigan, Oncology, Ann Arbor, Cytarabine, Hematology, Chemotherapy, United States, Bioengineering, Pharmacokinetics, Leukemia Gene Therapy, Acute Myeloid Leukemia, North and Central America, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC